TENAX THERAPEUTICS, INC.
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies for patients with pulmonary hypertension and related conditions. Its prioritized candidate is oral levosimendan, TNX-103, which it is evaluating in the LEVEL and LEVEL-2 Phase 3 trials for pulmonary hypertension in heart failure with preserved ejection fraction. The company also has TNX-201, a modified-release formulation of imatinib for pulmonary arterial hypertension, but has suspended plans for a Phase 3 trial while prioritizing levosimendan. Levosimendan is licensed from Orion Corporation, and Tenax holds rights to develop and commercialize its formulations. Tenax’s business centers on developing drug candidates, with plans to seek marketing authorization and commercialize products if approved. It contracts with third parties to manufacture its candidates and conduct preclinical and clinical work, and pursues collaborations and licensing or co-development arrangements. Tenax Therapeutics is headquartered in Chapel Hill, North Carolina.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Tenax Therapeutics reported a Q3 GAAP EPS of -$0.31, beating estimates by $0.05. The company had $113.7 million in cash as of September 30, 2026, and used $4.3 million in Q3.
TENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the
Nippon Life bought 162,024 Corebridge Financial (CRBG) shares for $5.59M. ADAR1 Capital acquired 922,849 Tenax Therapeutics (TENX) shares for $1.46M. Orrin H. Ingram II bought 29,081 FB Financial (FBK) shares for $1.54M. Troy A. Ignelzi purchased 5,500 Rapport Therapeutics (RAPP) shares for $143,550. Saba Capital bought $386,338 of ELLSWORTH GROWTH & INCOME FUND (ECF). Frank Slootman sold $94.9M of Snowflake (SNOW). Chevron (CVX) CLO sold $9.77M in shares.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TENX (TENAX THERAPEUTICS, INC.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent TENX coverage spans insider activity, financial news and earnings.
In the last 30 days, TENX insiders filed 3 SEC Form 4 transactions — 3 purchases ($1.5M) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 3 filings.
EPS beat may lift sentiment and support price.
Phase 3 failure and trial pause likely trigger sell pressure.
Significant insider buying at near 52‑week low.
Insider purchase signals confidence and may lift the stock.
The enrollment pause signals a delay in trial progress and may dampen near‑term investor sentiment.
AlphAI scores every news story that mentions TENX with an AI model for sentiment and relevance, and aggregates insider trades from TENAX THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenax Therapeutics reported a Q3 GAAP EPS of -$0.31, beating estimates by $0.05. The company had $113.7 million in cash as of September 30, 2026, and used $4.3 million in Q3.
TENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the
Nippon Life bought 162,024 Corebridge Financial (CRBG) shares for $5.59M. ADAR1 Capital acquired 922,849 Tenax Therapeutics (TENX) shares for $1.46M. Orrin H. Ingram II bought 29,081 FB Financial (FBK) shares for $1.54M. Troy A. Ignelzi purchased 5,500 Rapport Therapeutics (RAPP) shares for $143,550. Saba Capital bought $386,338 of ELLSWORTH GROWTH & INCOME FUND (ECF). Frank Slootman sold $94.9M of Snowflake (SNOW). Chevron (CVX) CLO sold $9.77M in shares.
ADAR1 Capital Management, LLC purchased 922,849 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.59 ($1.51–$1.66, $1.46M total) across 3 trades over 2026-10-19 to 2026-10-21. Filed jointly with Schneeberger Daniel (10% owner).
Tenax Therapeutics (TENX) paused LEVEL-2 enrollment to update inclusion criteria based on Phase 3 LEVEL trial results. The company aims to target sicker PH-HFpEF patients after seeing benefits in this subgroup. Tenax plans to seek FDA feedback and updated its investor presentation. The pause is not related to safety concerns.
Doogan Declan purchased 53,000 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.92 ($0.10M total) on 2026-09-16.
Giordano Christopher Thomas (CEO) purchased 10,850 shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.85 ($1.82–$1.88) across 2 trades over 2026-09-11 to 2026-09-15.
STAAB THOMAS R II (Chief Financial Officer) purchased 5,675 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.94 on 2026-09-11.
ING Groep N.V. and ING Capital Markets LLC filed an amended Schedule 13G/A, disclosing zero ownership in Tenax Therapeutics (TENX) as of September 11, 2026. The filing indicates no voting or dispositive power over Tenax's common stock, with 37,423,917 shares outstanding as of July 28, 2026.
ADAR1 Capital Management, LLC purchased 900,000 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at $1.78 ($1.60M total) on 2026-09-03. Filed jointly with Schneeberger Daniel (10% owner).
